Scientists at the University of California, San Francisco have initiated an expansive global research project known as CANOPY to investigate the biological and psychological effects of psychedelics in naturalistic, real-world environments. Recognizing that the vast majority of psychedelic experiences take place far outside formal academic laboratories, researchers designed the study to observe what these compounds do to human brains, bodies, and emotional well-being where consumption actually happens. The project intends to track as many as 3,000 individuals across the globe who are already planning to consume psychedelics at home, during organized retreats, or within other independent personal settings, allowing researchers to evaluate psychological changes at an unprecedented naturalistic scale.
Unlike conventional randomized clinical trials that supply pharmaceuticals and regulate experimental dosing schedules, the CANOPY project does not distribute substances or instruct volunteers to acquire or take any controlled drugs. Instead, the initiative operates as an observational, predominantly remote research study that registers adult participants who have already arranged their own psychedelic sessions.
The study evaluates an extensive spectrum of psychoactive and psychedelic substances commonly encountered outside clinical contexts, including psilocybin, lysergic acid diethylamide (LSD), ayahuasca, and ibogaine, along with MDMA and ketamine. Enrolled volunteers will complete a battery of standardized scientific assessments designed to measure psychological indicators, mood changes, and broader well-being.
Alongside widespread remote evaluations, the CANOPY protocol incorporates a comprehensive biological and physiological testing sub-study for a subset of participants able to travel to the UCSF campus. These individuals will undergo laboratory-based electroencephalography (EEG) and brain imaging, and they will supply blood and saliva samples prior to their scheduled psychedelic experiences.
Robin Carhart-Harris, PhD, a professor of neurology at UCSF and the lead investigator of CANOPY, noted that while existing scientific knowledge regarding psychedelics is derived primarily from tightly regulated laboratory settings, this trial applies systematic rigor to real-world experiences. Carhart-Harris explained that the goal is not merely to determine whether psychedelics can yield beneficial outcomes, but to understand for whom, under what specific circumstances, and through which mechanisms these outcomes occur. The team hopes the data will explain why individual responses vary dramatically and disentangle chemical drug actions from personal, biological, psychological, and environmental determinants.
The research is supported through federal funding from the Advanced Research Projects Agency for Health (ARPA-H), a division of the U.S. Department of Health and Human Services focusing on high-impact biomedical initiatives. CANOPY received an award of up to $1.4 million and represents one of three psychedelic studies at UCSF collectively awarded up to $8.5 million by ARPA-H. In parallel, Carhart-Harris is co-leading a $4 million project with Jennifer Mitchell, PhD, examining how psychological mindset and environmental setting impact psychedelic outcomes, while Mitchell and Lorenzo Pasquini, PhD, co-lead a third $3.1 million study investigating psychedelics in older adults exhibiting preclinical Alzheimer’s disease biomarkers.
Beyond its primary observational scope, CANOPY is architected as an overarching research platform intended to facilitate future targeted scientific investigations. Investigators anticipate that gathering granular observational data across thousands of self-directed experiences will provide critical safety and outcome benchmarks, helping scientists evaluate the potential risks and benefits of non-laboratory psychedelic use.
Researchers are currently recruiting adult participants who are already planning to use a psychedelic and are willing to complete the required research assessments for the project. Because the main study is conducted remotely, investigators do not supply participants with substances or instruct them to take drugs, and UCSF does not provide psychedelics or direct participants to obtain or use them. Individuals interested in enrolling can review detailed eligibility criteria, participation requirements, and enrollment information directly on the CANOPY study website.
The research is based at the University of California, San Francisco, an academic institution exclusively focused on the health sciences. UCSF is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF Health, which serves as UCSF’s primary academic medical system, includes top-ranked specialty hospitals and other clinical programs, and has affiliations throughout the Bay Area. In addition to its primary Bay Area facilities, the UCSF School of Medicine also has a regional campus in Fresno.
Subject of Research: Large-scale observational study of real-world psychedelic drug use and biological outcomes
Article Title: UCSF launches large-scale study of psychedelics in the real world
Article References: UCSF launches large-scale study of psychedelics in the real world. Original publication (Bibliographic details unavailable.)
Image Credits: AI Generated
DOI: Not provided
Keywords: UC San Francisco, CANOPY study, psychedelics, psilocybin, LSD, ayahuasca, ibogaine, MDMA, ketamine, Robin Carhart-Harris, ARPA-H, neuroimaging, electroencephalography, real-world evidence, wearable devices, biomarkers, psychological outcomes
News Source: Ophelia Keating. (November 14, 2026). UCSF Launches Observational Study Tracking Real-World Psychedelic Use in Thousands. Scienmag.



